The Quantellect read.As of Nov 19, 2026, 8 active firms cover Ligand Pharmaceuticals Incorporated: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $326.00 to $397.00, so the covering firms are broadly aligned. The average target of $352.63 sits 18% above the current $299.05. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.36 next quarter toward $11.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$352.63
+17.9% upside
Average target across 8 active firms as of Nov 19, 2026 vs $299.05 current
Highest Target$397.00
Average Target$352.63
Lowest Target$326.00
Detailed analyst forecasts for LGND
Showing 1–9 of 9 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate LGND a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LGND EPS & revenue forecast
EPS · NEXT QUARTER
$2.36
Range $2.31 – $2.41 · 2 analysts · +45% YoY
Next period, 2 analysts expect Ligand Pharmaceuticals Incorporated to earn $2.36 a share (range $2.31 – $2.41), versus $1.63 a year earlier. Full-year consensus is $9.58, growing to $11.95 the year after.
REVENUE · NEXT QUARTER
$76.1M
Range $76.1M – $76.1M · 2 analysts · +47% YoY
Revenue is expected to reach $76.1M (range $76.1M – $76.1M), +47.2% year-over-year. Full-year consensus is $291.7M, rising to $384.1M next year.
Top analysts covering Ligand Pharmaceuticals Incorporated
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LGND.
#1
Balaji Prasad
Barclays · Rank #226
Buy
$160.00-46.5% to target
Overall win rate
45%
+ Follow
#2
DM
Douglas Miehm
RBC Capital · Rank #263
Buy
$357.00+19.4% to target
Overall win rate
43%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$358.00+19.7% to target
Overall win rate
34%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$397.00+32.8% to target
Overall win rate
38%
+ Follow
#5
RW
Robert Wasserman
Benchmark · Rank #388
Buy
$335.00+12.0% to target
Overall win rate
41%
+ Follow
LGND stock forecast FAQ
What is LGND's average 12-month price target?+
The 8 active firms with a live target average $352.63 for Ligand Pharmaceuticals Incorporated over the next 12 months, ranging from a $397.00 high to a $326.00 low, as of Nov 19, 2026.
Is LGND stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for LGND?+
The Street-high target is $397.00 (Citigroup), and the Street-low is $326.00 (Oppenheimer). The average of all 8 active-firm targets is $352.63.
How many active Wall Street firms cover LGND?+
8 active firms have a recognized rating on Ligand Pharmaceuticals Incorporated as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LGND?+
Among analysts who currently cover LGND, Balaji Prasad of Barclays has the strongest overall Quantellect track record (Rank #226). Their current call is Buy with a $160.00 target.
What is Ligand Pharmaceuticals Incorporated's projected EPS for next quarter?+
The consensus estimate is $2.36 per share (range $2.31 – $2.41) across 2 analysts. Full-year EPS is projected at $9.58, rising to $11.95 the following year.
How much revenue is Ligand Pharmaceuticals Incorporated expected to report next quarter?+
Consensus revenue is $76.1M (range $76.1M – $76.1M). Full-year revenue is projected at $291.7M, growing to $384.1M next year.
Have analysts been upgrading or downgrading LGND lately?+
As of Nov 19, 2026, 8 of 8 active firms rate LGND a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LGND calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.